AHRQ NSAID final report
Executive Summary
Agency for Healthcare Research & Quality publishes final report on comparative effectiveness of osteoarthritis treatments. Report makes no significant departures from draft, which found that Pfizer's COX-2 inhibitor Celebrex has a safety benefit vs. non-selective NSAIDs (1"The Pink Sheet" Feb. 28, 2006, p. 23)...
You may also be interested in...
Celebrex Shows “Overall Net Benefit” Versus NSAIDs, AHRQ Draft Report Says
The safety benefit of Pfizer's COX-2 inhibitor Celebrex compared to non-selective nonsteroidal anti-inflammatory drugs is affirmed in a draft report from the Agency for Healthcare Research & Quality on osteoarthritis treatments
Setback For Athenex, Hanmi As CRL Requests New Trial
Hanmi partner Athenex has had a US complete response letter for its oral paclitaxel plus encequidar product for the treatment of metastatic breast cancer, amid concerns of safety risks associated with an increase in neutropenia-related sequelae. While the decision marks another setback for Hanmi in the US, Athenex is aiming to resolve the issues.
Chordia Looks To Forge Own Path In Oncology
Chordia only came into being in late 2017 but has already struck its first major licensing-out deal with a major pharma firm. It is now looking ahead to taking forward a portfolio of novel oncology assets originally acquired from investor Takeda.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: